|
|
|
|
|
|
|
Highlights from the 2024 ASCO Genitourinary Cancers Symposium |
|
|
|
|
| Subcutaneous Nivolumab Versus Intravenous Nivolumab in Patients With Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Pharmacokinetics, Efficacy, and Safety Results From CheckMate 67T |
| Saby George, MD, FACP |
| Saby George presented the results of CheckMate 67T, a phase 3 study comparing subcutaneous and intravenous nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma. The study aimed to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous nivolumab, providing an alternative administration option. |
|
|
|
|
|
| Belzutifan Versus Everolimus in Participants With Previously Treated Advanced Renal Cell Carcinoma: Patient-Reported Outcomes in the Phase 3 LITESPARK-005 Study |
| Thomas Powles, MBBS, MRCP, MD |
| Thomas Powles presented PROs from the phase 3 LITESPARK-005 study of belzutifan versus everolimus in patients with previously treated advanced RCC. Belzutifan was associated with meaningful improvements in symptom scores and physical functioning compared to everolimus, supporting its benefit in patients with advanced clear cell RCC after prior immune checkpoint and anti-angiogenic therapies. |
|
|
|
|
|
| Insights from CheckMate 67T and Patient-Reported Outcomes in LITESPARK-005 for Advanced RCC
|
| Ulka N. Vaishampayan, MBBS
|
| Ulka Vaishampayan discussed two studies. The first, comparing subcutaneous and intravenous nivolumab in RCC, found that NIVO SC demonstrated increased exposure and improved efficacy but raised concerns about higher anti-drug antibody rates. The second study, focusing on belzutifan vs. everolimus, showed better PROs with belzutifan, indicating potential benefits in disease-specific symptoms and quality of life for advanced renal cell carcinoma patients.
|
|
|
|
|
|
| The Role of Radiation in Primary Tumor and Distant Sites in Managing Renal Cell Carcinoma |
| Sophia Kamran, MD |
| Sophia Kamran discussed the role of radiation therapy in managing renal cell carcinoma (RCC). Contrary to historical beliefs, recent data supports the efficacy of SBRT for both primary RCC tumors and distant metastatic sites. SBRT has shown high local control rates with minimal toxicity and can be considered for medically inoperable patients with stage 1 or stage II/III kidney cancer. |
|
|
|
|
|
|
|
|
|
|
| Phase III Randomized Trial of Stereotactic Ablative Radiotherapy for Oligometastatic Advanced Renal Carcinoma (EA8211-SOAR)
|
| Raquibul Hannan, MD, Ph.D.
|
| The EA8211-SOAR is a phase 3 randomized trial, focusing on the management of oligometastatic advanced renal cell carcinoma (RCC). Dr. Raquibul Hannan discussed the trial, aiming to compare stereotactic ablative radiotherapy (SABR) to systemic therapy for patients with oligometastatic RCC, with the primary goal of assessing overall survival and Grade 3 toxicity as co-primary endpoints.
|
|
|
|
|
|
| Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment-Naive Patients with Advanced Clear Cell RCC
|
| Elshad Hasanov, MD, Ph.D.
|
| Elshad Hasanov presented a phase 1b/2 study, focusing on the combination of 177Lu girentuximab, cabozantinib, and nivolumab for treatment-naive patients with advanced clear cell renal cell carcinoma. The study aims to investigate whether the addition of 177Lu girentuximab to the standard regimen of cabozantinib and nivolumab can increase the complete response rate beyond the historical reference of 9%.
|
|
|
|
|
|
| Survivorship Issues Beyond 2 Years After Treatment in Testicular Germ Cell Tumors: Experience from a Large Center in the United Kingdom
|
| Jonathan Shamash, MB, ChB
|
| Jonathan Shamash presented a study that analyzed survivorship issues in testicular germ cell tumor patients beyond two years following treatment. Conducted at Barts Health NHS Trust, the study involved a retrospective review of patients with Stage 1 and metastatic germ cell tumors. The analysis revealed low relapse rates beyond two years post-treatment, particularly in those who received adjuvant treatment
|
|
|
|
|
|
| Longitudinal Tumor-Informed ctDNA Assay and Patient Outcomes in Testicular Cancer |
| Reuben Ben-David, MD |
| This study evaluated the utility of a longitudinal tumor-informed ctDNA assay in testicular cancer patients. The personalized ctDNA assay was used during the molecular residual disease and surveillance periods, demonstrating a significant association between ctDNA status and event-free survival. Positive ctDNA during these windows was linked to worse outcomes, highlighting the potential of ctDNA as a prognostic marker in testicular cancer. Further prospective studies are suggested to explore the clinical utility of ctDNA in this context. |
|
|
|
|
|
|
|
|
|
|
| Utility of Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Disease Monitoring in Patients with Non-Seminomatous Germ-Cell Tumor |
| Rebecca Hassoun, MD |
| This study investigated the utility of circulating tumor DNA as a predictive biomarker for disease monitoring in patients with non-seminomatous germ-cell tumors (NSGCT). The analysis included 25 patients with stage II and III NSGCT, with longitudinal ctDNA testing performed using the Signatera™ bespoke mPCR-NGS assay. The study found that ctDNA status post-primary Retroperitoneal Lymph Node Dissection and/or chemotherapy was significantly associated with event-free survival in NSGCT patients. |
|
|
|
|
|
| Evaluating Prognostic Models for Stage I Seminoma Within the Randomised Trial of Imaging and Surveillance in Seminoma Testis (TRISST) |
| Robert A. Huddart, PhD, MBBS, FRCR, MRCP |
| Robert Huddart discussed the evaluation of prognostic models for stage I seminoma within the randomized Trial of Imaging and Surveillance in Seminoma Testis (TRISST). Stage I seminoma is typically managed with surveillance following orchiectomy, but there is a need for effective risk stratification. The study utilized individual patient data from the TRISST cohort and identified tumor size ≥4 cm and pT3 disease as strongly associated with an increased rate of recurrence. |
|
|
|
|
|
|
|
|
|
|
|
